FY2025 · ended Dec 31, 2025 · Revenue $55, -60.4% YoY · Filed Jul 1, 2026
Goldenwell Biotech, Inc. (GWLL) files with the SEC under industry code 2000, Food and Kindred Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $55 and a net loss of $296,471. As of Jun 30, 2026 it held $11,143 in cash and investments and $0 in total debt.
Revenue (TTM)
$55
-60.4% vs year-ago TTM
Net income (TTM)
$-275,541
-98.1% vs year-ago TTM
Operating cash flow (TTM)
$-110,365
-474.5% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.00
Dividend per share
None
Shares outstanding
99.00M
+0.0% vs prior year
Net cash
$11,143
as of Jun 30, 2026
Operating margin
-196772.7%
FY 2026
Company profile
- Industry
- Food and Kindred Products (SIC 2000)
- Listed as
- GWLL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Solon, OH
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1800373
Other Food and Kindred Products companies
- Mondelez International, Inc. MDLZ
- Conagra Brands Inc. CAG
- CAMPBELL'S Co CPB
- Nomad Foods Ltd NOMD
- Flowers Foods Inc FLO
- Bellring Brands, Inc. BRBR
- Simply Good Foods Co SMPL
- Vital Farms, Inc. VITL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $55 | $139 | $2,340 | $47,800 | $15,967 |
| Operating income | -$113,326 | -$123,098 | -$115,826 | -$985,105 | — |
| Net income | -$296,471 | -$131,498 | -$117,361 | -$985,097 | -$116,981 |
| Diluted EPS | $0.00 | $0.00 | — | — | — |
| Operating cash flow | -$22,629 | -$123,077 | -$113,153 | -$1.1M | -$205,138 |
| Total assets | $36,120 | $224,192 | $228,094 | $248,400 | $460,979 |
| Total liabilities | $379,833 | $271,433 | $143,837 | $46,782 | $159,266 |
| Stockholders' equity | -$343,713 | -$47,241 | $84,257 | $201,618 | $301,713 |
| Cash and investments | $26,775 | $49,404 | $53,231 | $45,996 | $213,556 |
| Total debt | — | $173,985 | $0 | $25,372 | $47,779 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 29, 2026 | Sep 27, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jul 1, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Jul 1, 2026 | Dec 31, 2025 |
| 10-Q/A | Amended quarterly report | Jun 29, 2026 | Sep 30, 2025 |
All 85 Goldenwell Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.